A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Temozolomide (Primary)
Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pharyngeal neoplasms; Squamous cell cancer
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme Corp.

01 May 2016 This trial is prematurely ended in Portugal (end date: 10 May 2009), Sweden, Netherlands (end date: 10 May 2009), United kingdom and completed in Italy.
02 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
21 Nov 2009 Planned number of patients changed from 160 to 800 as reported by M.D. Anderson Cancer Center record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com